About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

ANG4043, a Brain-penetrant Peptide-monoclonal Antibody Conjugate, Effective in Treating HER2-positive Intracranial Tumors

by Dr. Trupti Shirole on December 10, 2014 at 9:42 AM
Font : A-A+

 ANG4043, a Brain-penetrant Peptide-monoclonal Antibody Conjugate, Effective in Treating HER2-positive Intracranial Tumors

Mice study by Angiochem has revealed that ANG4043, a peptide-monoclonal antibody (mAb) conjugate, entered the brain at therapeutic concentrations, resulting in significantly prolonged survival in mice. Angiochem is a biotechnology company creating and developing drugs that cross the blood-brain barrier (BBB).

mAb is directed against HER2, which is the protein targeted by Herceptin. As mAb is conjugated to Angiopep-2, it is recognized by the LRP1 receptor and takes advantage of a receptor-mediated transcytosis mechanism to cross the BBB. Angiochem researchers found that ANG4043 binds LRP1 receptors while retaining the pharmacological properties of the native anti-HER2 mAb, including high affinity HER2 binding and anti-proliferative activity in HER2-expressing cells. ANG4043 achieves therapeutic brain concentrations in healthy mice and in mice bearing HER2+ intracranial tumors. Treatment with ANG4043 (15 mg/kg IV, twice-weekly) increased median survival time by 78% (80 days compared to 45 days for control).

Advertisement

Jean Lachowicz, Ph.D., CSO at Angiochem, said, "While our current data has focused on demonstrating the potential of Angiochem's technology in oncology, its applicability extends beyond oncology to include neurodegenerative diseases as well." The clinical study titled 'ANG4043, a Novel Brain-penetrant Peptide-mAb Conjugate, is Efficacious against HER2-positive Intracranial Tumors in Mice' is published in Molecular Cancer Therapeutics.

Source: Medindia
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Cancer News

Why Is Time of Day Important in Cancer Diagnosis and Treatment?
Chronotherapy (the sleep-wake cycle) is observed as a valuable alternative treatment in cancer diagnosis and treatment.
How Do Neutrophils Impact Pancreatic Cancer Treatment Resistance?
A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.
Lung Cancer: The Survival Advantage of Lobectomy Over Wedge Resection
The survival rates between lobectomy and wedge resection surgical procedures were found to be the same among lung cancer patients.
Could TKI Cancer Drugs Lead to Inflammatory Side Effects?
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Are Biomarkers the Key to Identifying Early Pancreatic Risk?
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

ANG4043, a Brain-penetrant Peptide-monoclonal Antibody Conjugate, Effective in Treating HER2-positive Intracranial Tumors Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests